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Introduction
Tremor is one of the most commonly 
encountered neurological signs, and it may be 
a feature of a variety of neurological diseases. 
Action tremor, which occurs with voluntary 
movement, is the hallmark feature of essen­
tial tremor (ET), which is considered one of 
the most prevalent neurological diseases, and 
prevalence increases with age. Despite the 
ubiquity of tremor among the elderly, there 
are limited data on the role of environmental 
exposures that are potentially modifiable. 
Lead is one environmental neurotoxicant that 
has been suspected as a risk factor for ET 
(Louis 2008).
Case–control studies in two settings have 
examined the association between elevated 
blood lead concentration and ET (Centers 
for Disease Control and Prevention 2014; 
Dogu et al. 2007; Louis et al. 2003, 2005): 
one based in the New York metropolitan area 
and the other in Mersin, Turkey. In each 
setting, the risk of ET was found to be higher 
with higher blood lead concentrations. In 
New York, a strong modification by a poly­
morphism in the δ­aminolevulinic acid dehy­
drogenase (ALAD) gene was seen (Louis et al. 
2005). However, blood lead has a half­life 
of approximately 30 days (Hu et al. 1998; 
Rabinowitz 1991) and is more a biomarker 
of recent exposure than of chronic exposure 
to environmental lead. If lead­induced neuro­
toxicity results in ET, or more broadly in 
action tremor, it is likely chronic exposure 
may be more relevant.
To examine the association between 
chronic lead exposure and action tremor, we 
used data from participants in the Department 
of Veterans Affairs (VA) Normative Aging 
Study (NAS), a cohort of community­
dwelling elderly men in the Greater Boston, 
Massachusetts, area with measures of lead 
in bone (a biomarker of cumulative lead 
exposure) and blood (a biomarker of recent 
exposure) and measures of tremor.
Methods
Study sample. Our study sample is a subgroup 
of the NAS, a longitudinal study of aging 
established by the VA in 1963 when 2,280 
men from the Greater Boston area who were 
21–80 years of age were enrolled (Bell et al. 
1966). Men with a history of treatment 
for hypertension, systolic blood pressure 
> 140 mmHg, diastolic blood pressure 
> 90 mmHg, or other chronic conditions, 
including heart disease, diabetes mellitus, and 
cancer, were not admitted into the study. 
NAS subjects have reported for medical 
examinations every 3–5 years, at which data 
on smoking history, education level, food 
intake, and other risk factors that may influ­
ence health were also collected. Cognitive 
testing results have been collected since 1993. 
The human research committees of the VA, 
Partners Health Care, and Harvard School 
of Public Health approved this research, 
and written consent was obtained from 
all participants.
Of 1,287 active NAS participants when 
bone lead measurements began in 1991, 878 
(68%) gave their consent for K­shell X­ray 
fluorescence (KXRF) measurements of lead 
concentration in both tibia and patella bone. 
NAS participants with KXRF measure­
ments were similar to those without them 
with respect to distributions of age, race, 
education, smoking status, consumption 
of alcohol, and retirement status, although 
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Background: Tremor is one of the most common neurological signs, yet its etiology is poorly 
understood. Case–control studies suggest an association between blood lead and essential tremor, 
and that this association is modified by polymorphisms in the δ-aminolevulinic acid dehydrogenase 
(ALAD) gene.
oBjective: We aimed to examine the relationship between lead and tremor, including modification 
by ALAD, in a prospective cohort study, using both blood lead and bone lead—a biomarker of 
cumulative lead exposure.
Methods: We measured tibia (n = 670) and patella (n = 672) bone lead and blood lead (n = 807) 
among older men (age range, 50–98 years) in the VA Normative Aging Study cohort. A tremor 
score was created based on an approach using hand-drawing samples. ALAD genotype was dichoto-
mized as ALAD-2 carriers or not. We used linear regression adjusted for age, education, smoking, 
and alcohol intake to estimate the associations between lead biomarkers and tremor score.
results: In unadjusted analyses, there was a marginal association between quintiles of all lead 
biomarkers and tremor scores (p-values < 0.13), which did not persist in adjusted models. Age was 
the strongest predictor of tremor. Among those younger than the median age (68.9 years), tremor 
increased significantly with blood lead (p = 0.03), but this pattern was not apparent for bone lead. 
We did not see modification by ALAD or an association between bone lead and change in tremor 
score over time.
conclusion: Our results do not strongly support an association between lead exposure and 
tremor, and suggest no association with cumulative lead biomarkers, although there is some 
suggestion that blood lead may be associated with tremor among the younger men in our cohort.
citation: Ji JS, Power MC, Sparrow D, Spiro A III, Hu H, Louis ED, Weisskopf MG. 2015. Lead 
exposure and tremor among older men: the VA Normative Aging Study. Environ Health Perspect 
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they tended to have slightly higher blood 
lead concentrations (Hu et al. 1996). We 
excluded individuals with patella measure­
ment uncertainty > 15 μg/g (n = 3) and 
tibia measurement uncertainty > 10 μg/g 
(n = 11) because these usually reflect exces­
sive subject movement during the measure­
ment. We also excluded nonwhites (n = 19) 
because there were too few to consider 
separately. Diagnoses of ET were not 
assigned in NAS; however, it was possible 
to assess action tremor because participants 
produced drawings as part of cognitive tests 
that required them to copy different figures. 
These figure­drawing samples were completed 
a median of 13 (interquartile range, 41–0) 
days before the bone lead measurements. Of 
those with valid bone lead measures, 672 
subjects with a patella lead measurement and 
670 subjects with a tibia lead measurement 
also completed the cognitive testing that 
included figure copying. Blood was collected 
from virtually all participants at their regu­
larly scheduled VA clinic visits and was used 
to measure blood lead concentration. We 
analyzed data from the 807 NAS participants 
who had blood drawn (used for lead measure­
ment) on the same day as they completed the 
figure copying.
Blood lead assessment. Blood lead samples 
were collected in a special lead­free tube 
containing EDTA. Blood samples were sent 
to ESA Laboratories (Chelmsford, MA) for 
analysis by Zeeman background­corrected 
flameless atomic absorption (graphite furnace) 
calibrated with National Institute of Standards 
and Technology (NIST) Blood Lead Standard 
Reference Materials. Ten percent of the 
samples were run in duplicate, 10% were stan­
dards, and 10% were blanks, analysis of which 
produced no evidence of external contamina­
tion or significant problems with reliability. 
In tests on reference samples from the Centers 
for Disease Control and Prevention, the 
 coefficients of variation were 1–8%.
Bone lead assessment. Bone lead concentra­
tion measurements were taken with a KXRF 
instrument (ABIOMED, Danvers, MA) at 
both the mid­tibia shaft (midpoint between 
the tibial plateau and the medial malleolus) 
and patella while the subject was seated. 
Mid­tibia (shin bone) is composed primarily 
of cortical bone with a lead half­life of many 
decades; patella (knee cap bone) is primarily 
trabecular bone and has a lead half­life of a 
few years (Wilker et al. 2011). Thirty­minute 
measurements were taken at each site, after the 
skin at each measurement site had been washed 
with a 50% solution of isopropyl alcohol. The 
KXRF beam collimator was sited perpendic­
ular to the flat bony surface of the tibia and at 
30° in the lateral direction for the patella.
ALAD genotype assessment. Previous 
studies suggest effect modification by ALAD 
genotype (Louis et al. 2005). The ALAD 
gene is located on chromosome 9q32, and 
the reference SNP (single nucleotide poly­
morphism) identification number for the 
polymorphism is rs1800435. We determined 
participants’ ALAD genotype through ampli­
fications on 0.5 μL of whole blood using two 
sets of primers specific for a portion of the 
ALAD gene. Primer sequences for the initial 
round of amplification were (5´­AGAC 
A G A C  A T T A  G C T C  A G T A ­ 3 ´ )  a n d 
(5´­GGCA AAGA ACAC GTCC ATTC­3´). 
Amplified DNA was then restricted using 
MSPI and electrophoresed through 2.0% 
agarose. ALAD alleles are differentiated based 
on the existence of a MSPI endonuclease 
restriction site specific to the ALAD-2–
derived PCR (polymerase chain reaction) 
fragment, which yields a diagnostic restric­
tion band. Heterozygotes exhibit both the 
ALAD-1 and ALAD-2 fragments and can 
thus be differentiated from homozygotes of 
either type. We performed PCR reactions 
in duplicate, with blank controls included 
in each set (Bradley and Mash 2009). We 
combined ALAD 1­2 and 2­2 groups as a 
single indicator variable and used ALAD 1­1 
as the reference group (Caller et al. 2012).
Tremor assessment. Numerical ratings of 
tremor were assigned based on hand­drawn 
samples as described in previous studies 
(Hoffman et al. 2012; Vieira et al. 2012). 
These scores represent action tremor, which 
we hereafter refer to simply as tremor. The 
hand­drawn samples were derived from figure­
copying testing performed as part of a larger 
cognitive test battery. The copying included 
items from the Consortium to Establish a 
Registry for Alzheimer’s Disease (CERAD) 
battery, Mini­Mental State Examination 
(MMSE), and developmental test of visual–
motor integration (VMI) (Welsh et al. 1994). 
A research assistant was trained in­person 
by a senior movement disorders neurologist 
who specializes in tremor disorders (E.D.L.) 
to rate the severity of tremor based on eight 
drawings of figures. Visual examples from 
25 NAS participants with a range of tremor 
severity were used for this 4­hr in­person 
training; thus 200 drawings were co­rated and 
discussed in detail. Tremor on each figure was 
rated using an ordinal scale: 0 (no tremor), 
0.5 (possible tremor), 1 (clear tremor that 
was mild), 1.5 (mild to moderate tremor), 2 
(moderate tremor). Based on the eight rated 
items, a total tremor score was generated for 
each subject by summing the scores for each 
of the eight figures (possible range, 0–16). 
During the course of subsequent post­training 
ratings, interrater agreement was high (Pearson 
correlation, 0.82), based on 20% of samples 
randomly selected for independent co­rating 
by the rater and the neurologist to assess 
interrater agreement in total tremor scores. 
Based on previously established cut­off points 
(Hoffman et al. 2012), drawing samples from 
participants whose total tremor score was ≥ 4.5 
were sent to the senior neurologist (E.D.L.), 
who made a final determination of whether 
or not the tremor was sufficient to be consid­
ered moderate tremor in the range of essential 
tremor, which we refer to hereafter as elevated 
tremor; this assignment was based on the 
presence of clear tremor of moderate ampli­
tude in two or more drawings in the absence 
of medications that could induce tremor (e.g., 
lithium, valproate), Parkinson’s disease by 
history, or hyperthyroidism by history.
Statistical methods. We used linear regres­
sion to assess the association between lead 
biomarkers, categorized into quintiles, and 
continuous tremor scores in our primary 
analyses. The significance of the trend was 
assessed by assigning to each person the 
median of their lead biomarker quintile, 
and using this variable to test for linear 
trends. This approach reduces the influ­
ences of extreme exposure values. Covariates 
considered in the models taken from the 
regular NAS questionnaires included age 
(years), age squared, alcohol (none and tertiles 
of consumption), pack­years of smoking 
(nonsmokers and tertiles among smokers), 
and education level (less than high school, 
high school graduate, less than college, and 
college graduate and beyond college). In 
secondary analyses we considered the dichoto­
mous outcome of elevated tremor defined by 
the study neurologist, and used logistic regres­
sion to estimate the odds ratio (OR) and 95% 
confidence interval (CI) by levels of the lead 
biomarkers. We also conducted several sensi­
tivity analyses. First, the analyses described 
above were repeated with lead biomarkers 
treated as continuous variables, both as 
untransformed and after log transformation. 
Second, we evaluated whether additional 
adjustment for ALAD status or medica­
tions, specifically self­reported use of beta­
blockers (AHFS Pharmacologic­Therapeutic 
Classification code 24:24; http://www.
ahfsdruginformation.com/pt­classification­
system.aspx) and calcium channel blockers 
(AHFS  Pha rmaco log i c ­The r apeu t i c 
Classification code 24:28) at the time of 
tremor assessment, affected our results. Beta­
blockers such as propranolol and primidone 
are first­line treatments for ET, and can 
produce a reduction in tremor (Murch et al. 
2004; Pablo et al. 2009). Calcium channel 
blockers, such as nifedipine, are used to 
treat high blood pressure and may also affect 
tremor (Alonso et al. 2010). Because < 5% 
of the study population reported using 
anti convulsants, thyroid agents, or anti­
parkinsonian agents, we chose not to consider 
these medications. Additionally, using strati­
fied analyses, we evaluated whether there was 
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an effect of lead, categorized into quintiles, on 
tremor, treated as a continuous variable, in 
subgroups defined by ALAD and use of beta­
blockers and/or calcium channel blockers. 
Because many more factors may contribute 
to tremor in older age, making the detection 
of a subtle environmental contributor more 
difficult to detect, we also examined the asso­
ciation between lead and tremor score sepa­
rately among those below or at and above the 
median age (68.9 years).
Finally, using the most recently avail­
able figure­copying samples from subsequent 
follow­up assessments of the NAS partici­
pants, we were able to obtain a second assess­
ment of tremor (mean ± SD = 8.0 ± 3.2 years 
after the first assessment) in 427 participants 
with bone lead assessments who had an initial 
tremor score of < 4.5. We then used linear 
regression to estimate the association between 
quintile of lead biomarker data and change 
in tremor score in this group. All analyses 
were performed using SAS version 9.2 (SAS 
Institute Inc., Cary, NC).
Results
The men in our study ranged in age from 50 
to 98 years, with mean (± SD) of 69.0 ± 7.2 
years. Overall, the mean blood lead concentra­
tion was 5.0 ± 2.7 μg/dL, and the mean tibia 
and patella bone lead were 21.2 ± 13.3 and 
28.0 ± 18.4 μg/g, respectively. The medians 
for blood, tibia, and patella were 4.0 μg/dL, 
19.0 μg/g, and 24.0 μg/g, respectively. The 
correlations between lead measurements were 
high (Spearman correlation = 0.66 for patella 
and tibia; 0.40 for both patella and blood; 
0.38 for tibia and blood). The distribution of 
lead concentrations by different characteristics 
of the study sample is shown in Table 1. As 
has been reported previously (Hu et al. 1996), 
lead concentrations increase with higher age, 
lower education, and more smoking.
Tremor ratings among the 807 partici­
pants with blood lead measurements ranged 
from 0.5 to 11.5, with a mean (± SD) of 
3.96 ± 1.01, median of 4.0, and an inter­
quartile range of 3.5–4.0. As has been 
reported previously, we found that tremor 
scores increased with age, and this persisted 
when adjusted for education, smoking, 
and alcohol consumption (Louis 2008). In 
adjusted linear regression analyses, tremor 
score increased 0.25 points per 10 years 
of age (p­value < 0.001). In unadjusted 
analyses, there was a marginal association 
between quintiles of all lead biomarkers 
and total tremor scores (p­values = 0.11 for 
blood, 0.07 for patella, 0.13 for tibia), yet in 
adjusted models, we did not find an associa­
tion between quintiles of lead biomarkers and 
total tremor scores (Table 2). In unadjusted 
analyses, there was only a marginal association 
between having elevated tremor and quintile 
of tibia lead, but this association was not 
significant in adjusted analyses (Table 3). The 
results were similarly null when lead measures 
were analyzed as continuous variables either 
untransformed or log transformed, after 
additional adjustment for ALAD genotype or 
use of beta­blockers and/or calcium channel 
blockers, and in subgroups defined by ALAD 
genotype or beta­blocker/calcium channel 
blocker medication use (data not shown).
Among those younger than the median 
(68.9 years), tremor score increased signifi­
cantly with increasing quintile of blood lead 
(p = 0.03) with those in the highest quintile 
scoring 0.35 (95% CI: 0.03, 0.67) points 
higher than those in the lowest quintile 
(Table 4). This pattern was not apparent for 
either bone lead biomarker. Among those at 
least as old as the median age, there was no 
association between any lead biomarker and 
total tremor score.
Finally, we also analyzed the change in 
tremor scores from baseline assessment to 
assessments an average of 8.0 ± 3.2 years 
after bone lead measurement. Among NAS 
men who scored < 4.5 on the first tremor 
assessment, we found no association between 
bone lead biomarkers and change in tremor 
score (Table 5).
Table 1. Lead biomarker and tremor scores by demographic characteristics of study population.
Characteristic
Blood lead Patella lead Tibia lead
n
Mean ± SD 
(μg/dL)
Tremor score 
(mean ± SD) n
Mean ± SD 
(μg/g)
Tremor score  
(mean ± SD) n
Mean ± SD 
(μg/g)
Tremor score  
(mean ± SD)
Total 807 5.01 ± 2.72 3.96 ± 1.01 672 27.98 ± 18.38 3.99 ± 0.98 670 21.23 ± 13.29 3.99 ± 0.99
Age (years)         
 < 55 16 3.88 ± 2.06 3.72 ± 0.48 12 12.67 ± 4.89 3.63 ± 0.48 12 10.50 ± 5.57 3.63 ± 0.48
55–59 63 4.30 ± 1.92 3.67 ± 0.83 48 18.79 ± 11.31 3.71 ± 0.71 48 12.28 ± 6.74 3.64 ± 0.85
60–64 176 4.82 ± 2.51 3.89 ± 0.97 143 23.33 ± 11.29 3.92 ± 0.96 143 18.28 ± 10.16 3.92 ± 0.96
65–69 190 5.07 ± 2.49 3.92 ± 0.89 172 27.71 ± 18.51 3.94 ± 0.83 174 20.41 ± 12.32 3.94 ± 0.83
70–74 206 5.14 ± 2.85 3.87 ± 0.82 170 31.62 ± 22.15 3.88 ± 0.78 168 24.28 ± 15.11 3.88 ± 0.78
75–79 98 5.28 ± 3.63 4.29 ± 1.37 85 31.07 ± 17.61 4.34 ± 1.28 82 23.52 ± 11.19 4.34 ± 1.30
80–84 45 5.58 ± 2.70 4.16 ± 0.89 34 39.76 ± 21.85 4.26 ± 0.72 35 31.91 ± 19.05 4.20 ± 0.81
≥ 85 13 5.46 ± 2.26 5.65 ± 2.14 8 34.61 ± 11.47 6.31 ± 2.49 8 27.30 ± 13.33 6.31 ± 2.49
Education      
Missing 33 4.67 ± 2.15 3.88 ± 0.99 26 27.84 ± 19.30 3.83 ± 0.62 26 18.13 ± 9.82 3.83 ± 0.62
College graduate and beyond 211 4.64 ± 2.31 4.00 ± 1.18 192 22.93 ± 13.22 4.04 ± 1.18 191 17.10 ± 10.12 4.04 ± 1.19
Less than college 203 4.65 ± 2.40 3.90 ± 1.10 167 25.79 ± 16.08 3.97 ± 1.05 167 20.90 ± 11.30 3.94 ± 1.09
High school graduate 283 5.38 ± 3.21 3.97 ± 0.81 222 31.59 ± 20.88 3.99 ± 0.76 223 23.52 ± 14.93 3.98 ± 0.76
Less than high school 77 5.74 ± 2.60 4.04 ± 1.00 65 36.21 ± 22.25 4.01 ± 0.90 63 27.77 ± 17.15 4.03 ± 0.91
Alcohol consumption         
Nondrinker 211 4.74 ± 2.28 4.07 ± 1.16 180 28.46 ± 17.06 4.06 ± 1.17 178 22.47 ± 12.44 4.06 ± 1.17
Tertile 1 of drinkers 197 4.41 ± 2.42 3.89 ± 0.96 160 24.68 ± 16.91 3.94 ± 0.93 161 19.75 ± 12.54 3.93 ± 0.94
Tertile 2 of drinkers 194 5.14 ± 3.05 3.87 ± 0.89 163 28.57 ± 21.28 3.90 ± 0.78 161 21.47 ± 15.35 3.88 ± 0.83
Tertile 3 of drinkers 191 5.75 ± 2.98 4.03 ± 0.98 162 30.18 ± 17.96 4.06 ± 0.94 163 21.14 ± 12.46 4.06 ± 0.93
Missing 14 5.36 ± 2.27 3.71 ± 1.40 7 26.00 ± 14.06 4.14 ± 1.41 7 20.14 ± 18.72 4.14 ± 1.41
Smoking      
Nonsmoker 218 4.90 ± 2.62 3.98 ± 1.11 196 25.57 ± 16.21 4.04 ± 0.92 201 19.74 ± 12.43 4.00 ± 0.96
Tertile 1 of pack-years 187 4.75 ± 2.89 3.89 ± 0.84 160 25.61 ± 16.58 3.86 ± 0.87 158 20.75 ± 12.63 3.86 ± 0.87
Tertile 2 of pack-years 201 4.88 ± 2.24 3.86 ± 0.93 152 27.00 ± 16.36 3.92 ± 0.92 151 20.44 ± 11.07 3.93 ± 0.92
Tertile 3 of pack-years 189 5.52 ± 3.06 4.12 ± 1.14 153 34.27 ± 22.77 4.15 ± 1.19 150 24.32 ± 16.21 4.15 ± 1.20
Missing 12 5.08 ± 3.12 4.08 ± 0.51 11 31.18 ± 20.42 4.05 ± 0.57 10 24.30 ± 16.95 4.00 ± 0.58
ALAD         
1-1 684 5.09 ± 2.80 3.99 ± 1.04 564 28.07 ± 18.73 4.00 ± 1.00 561 21.24 ± 13.75 3.99 ± 1.02
1-2 and 2-2 123 4.55 ± 2.18 3.84 ± 0.86 108 27.47 ± 16.50 3.99 ± 0.83 109 21.17 ± 10.69 3.99 ± 0.83
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Discussion
In this cohort of community­dwelling elderly 
men, although unadjusted analyses were 
marginally significant, we did not find a 
signifi cant overall association between blood or 
bone lead exposure biomarkers and ratings of 
action tremor or occurrence of elevated tremor 
after adjustment for potential confounders. 
Nor did we find this association to be modified 
by poly morphisms in the ALAD gene or by 
medication use. However, in an analysis that 
stratified by age, a significant association 
between higher blood lead concentration and 
worse tremor was seen among the younger 
half of NAS men in our study sample after 
adjustment for confounders, although this was 
weaker for bone lead. We found no association 
between bone lead and change in tremor over 
an average of 8 years of follow­up.
Older men are likely to have many more 
factors that contribute to tremor, including 
age itself as well as some medications and 
accumulating comorbidities that can affect 
tremor, such as hyperthyroidism. These other 
factors could obscure an association with lead 
and explain why we found an association 
only among the younger men. Alternatively, 
because participation in a cohort and follow­
up within a cohort is often greater among 
healthier individuals (Alonso et al. 2009; Mein 
et al. 2012)—and absence of chronic condi­
tions or their symptoms was an entry crite­
rion for the NAS—this could have resulted 
in some selection of NAS participants and the 
subsample in our analysis that are less sensi­
tive to the effects of lead. People more sensi­
tive to lead would have been more likely to 
exhibit conditions that would either exclude 
them from participation or at least make 
them less likely to participate or continue to 
participate. This selection would be expected 
to be stronger among older individuals 
because more of their contemporaries would 
be showing such symptoms and conditions. 
Thus, we may see stronger associations among 
the younger half of our sample because the 
younger half is less selected for insensitivity to 
lead effects.
Because we a priori expected that cumu­
lative lead exposure would be a stronger 
predictor of tremor than recent exposure, the 
lack of association with bone lead—a much 
better biomarker of cumulative exposure than 
blood lead—is puzzling. A concern with such 
a pattern of results is that it suggests that the 
association could be driven by reverse causa­
tion, whereby some aspect of tremor results 
in more bone loss and, thus, increased blood 
lead as lead is released from bone stores. 
However, no data suggest that persons with 
tremor or ET lose bone more rapidly than 
those without. One possibility is that lead­
related effects contribute to tremor only if 
some other necessary event has occurred, 
at which point the lead­related effects—for 
example, neuroinflammation as a result of 
lead­induced oxidative stress—come into play 
with more immediate consequences. It is also 
possible that current lead burden acting via 
acute effects on the nervous system promotes 
tremor, rather than longer­term neurotoxic 
effects of lead. We also cannot rule out 
chance as an explanation for this result.
There is a limited literature exploring risk 
factors for tremor generally or for ET more 
Table 3. Odds ratio (OR) for elevated tremor by lead biomarker quintiles.
Logistic regression Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 p-Trend
Blood lead      
Case/noncases (n) 24/220 16/162 12/110 17/136 11/99
Lead range (μg/dL) 0 to 3 4 to 4 5 to 5 6 to 7 8 to 28
Crude OR (95% CI) Reference 0.91 (0.47, 1.76) 1.00 (0.48, 2.08) 1.15 (0.59, 2.21) 1.02 (0.48, 2.16) 0.80
Adjusteda OR (95% CI) Reference 0.96 (0.49, 1.90) 0.87 (0.40, 1.85) 1.03 (0.52, 2.04) 0.84 (0.38, 1.86) 0.72
Patella lead      
Case/noncases (n) 10/144 14/115 16/111 13/118 13/118
Lead range (μg/g) –9 to 15 16 to 21 22 to 28 29 to 39 40 to 165
Crude OR (95% CI) Reference 1.75 (0.75, 4.09) 2.08 (0.91, 4.75) 1.59 (0.67, 3.75) 1.59 (0.67, 3.75) 0.51
Adjusteda OR (95% CI) Reference 1.51 (0.62, 3.64) 1.57 (0.66, 3.75) 1.29 (0.52, 3.21) 0.83 (0.31, 2.19) 0.41
Tibia lead      
Case/noncases (n) 13/129 8/116 12/124 12/121 19/116
Lead range (μg/g) –1 to 11 12 to 16 17 to 21 22 to 29 30 to 126
Crude OR (95% CI) Reference 0.68 (0.27, 1.71) 0.96 (0.42, 2.19) 0.98 (0.43, 2.24) 1.63 (0.77, 3.44) 0.09
Adjusteda OR (95% CI) Reference 0.63 (0.25, 1.62) 0.84 (0.36, 1.99) 0.79 (0.33, 1.89) 1.08 (0.46, 2.53) 0.60
aAdjusted for age, age squared, alcohol intake, cigarette pack-years, and education level.
Table 2. Difference in tremor scores by lead biomarker quintiles.
Linear regression Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 p-Trend
Blood lead   
n 244 178 122 153 110
Tremor score (mean ± SD) 3.89 ± 1.02 3.96 ± 1.10 3.98 ± 0.74 4.01 ± 1.03 4.06 ± 1.11
Lead range (μg/dL) 0 to 3 4 to 4 5 to 5 6 to 7 8 to 28
Crude model (95% CI) 0 (reference) 0.07 (–0.13, 0.26) 0.09 (–0.13, 0.31) 0.12 (–0.08, 0.33) 0.18 (–0.05, 0.41) 0.11
Adjusteda model (95% CI) 0 (reference) 0.09 (–0.10, 0.29) 0.06 (–0.16, 0.28) 0.07 (–0.13, 0.27) 0.07 (–0.16, 0.30) 0.62
Patella lead      
n 154 129 127 131 131
Tremor score (mean ± SD) 3.97 ± 1.01 3.98 ± 1.05 3.93 ± 0.68 3.87 ± 0.88 4.22 ± 1.16
Lead range (μg/g) –9 to 15 16 to 21 22 to 28 29 to 39 40 to 165
Crude model (95% CI) 0 (reference) 0.01 (–0.22, 0.23) –0.04 (–0.27, 0.19) –0.10 (–0.33, 0.12) 0.24 (0.02, 0.47) 0.07
Adjusteda model (95% CI) 0 (reference) –0.07 (–0.30, 0.15) –0.14 (–0.37, 0.09) –0.22 (–0.45, 0.01) –0.02 (–0.27, 0.22) 0.67
Tibia lead   
n 142 124 136 133 135
Tremor score (mean ± SD) 3.88 ± 1.02 3.92 ± 1.06 4.00 ± 0.95 4.11 ± 0.98 4.02 ± 0.93
Lead range (μg/g) –1 to 11 12 to 16 17 to 21 22 to 29 30 to 126
Crude model (95% CI) 0 (reference) 0.04 (–0.20, 0.28) 0.12 (–0.11, 0.36) 0.23 (–0.01, 0.46) 0.14 (–0.10, 0.37) 0.13
Adjusteda model (95% CI) 0 (reference) 0.03 (–0.20, 0.26) 0.03 (–0.20, 0.26) 0.13 (–0.11, 0.36) –0.07 (–0.32, 0.17) 0.70
aAdjusted for age, age squared, alcohol intake, cigarette pack-years, and education level.
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specifically, and lead exposure in particular. 
The prior studies differed from the present 
study in that they considered clinical ET in 
a case–control study design with only blood 
lead as a measure of exposure (Dogu et al. 
2007; Louis et al. 2003, 2005). In a New York 
study, 100 ET patients were identified from 
a computer database at a medical center in 
New York, and 143 controls were identified 
using random­digit dialing in the New York 
City metropolitan area and matched on age 
strata, sex, and ethnicity (Louis et al. 2003). 
Blood lead concentration was higher in the 
ET patients (mean, 3.3 ± 2.4 μg/dL) than in 
controls (mean, 2.6 ± 1.6 μg/dL). For each 
unit change of blood lead, the adjusted OR 
for ET was 1.19 (95% CI: 1.05, 1.39). In a 
hospital­based study in Mersin, Turkey, 105 
ET cases were selected randomly from regis­
tration codes, and 105 controls were recruited 
from spouses or relatives of the cases (Dogu 
et al. 2007). ET cases had a median blood 
lead of 2.7 μg/dL, and controls had a median 
of 1.5 μg/dL. A 1­μg/dL increase in blood 
lead was associated with an OR for ET of 
4.01 (95% CI: 2.53, 6.37). These results are 
in the same direction as the New York–based 
study, although the much stronger asso­
ciation could suggest some bias and highlights 
the need for further study in a prospective 
cohort setting. The age of study participants 
in the New York study was similar to those 
in our present study, but participants in the 
Turkish study were much younger (control 
mean, 51 ± 14 years). In our study popula­
tion, the mean and median of blood lead 
concentrations were slightly higher than in 
the previous case–control studies, so exposure 
differences are not likely to explain the 
discrepant findings.
In another report, carriers of the ALAD-2 
allele showed a significantly larger odds of ET 
per unit increase in blood lead compared with 
those with ALAD­1­1 genotype (Louis et al. 
2005). We did not find evidence for such an 
interaction for tremor scores. The ALAD-2 
protein binds more tightly to lead ions than 
the ALAD-1 protein, although whether this 
confers greater toxicity to a given exposure to 
lead is unclear. In other studies in the NAS, 
interactions between lead and ALAD genotype 
have been seen in opposite directions for 
performance on a spatial copying task and 
mood symptoms (Rajan et al. 2007, 2008), 
whereas no interaction was seen for perfor­
mance on several other cognitive tests (Rajan 
et al. 2008; Weuve et al. 2006).
Our study is the first to investigate the 
association between lead and tremor using 
bone lead concentration, a biomarker of 
cumulative lead exposure, and the first 
to explore this in a large cohort study. 
Nonetheless, there are limitations of our study 
that need to be considered as well. First, our 
findings were only among men, and thus 
may not be generalizable to women. Second, 
because high lead exposure is associated with 
various health ailments, it is possible that NAS 
participants with higher lead concentrations 
were less likely to participate in the bone lead 
or cognitive testing assessments. Thus, if the 
nonparticipation was also preferentially among 
men with more tremor, then our results would 
be biased downward. Perhaps most impor­
tant, we used drawing samples to assess tremor 
severity, not a clinical examination. Although 
this tremor rating is not a clinical assessment 
of ET, it is an approach that has been used for 
prevalence estimation of ET (Hoffman et al. 
2012), and we did find that tremor ratings 
increased with age as expected, validating to 
some extent our tremor assessment. However, 
not being a clinical assessment of ET, our 
tremor assessment may have been influenced 
by many factors other than ET itself. This 
would likely be more of a concern among 
older participants, and in fact we found results 
more in line with the prior ET case–control 
studies among the younger half of men in our 
sample (Louis 2008).
Conclusions
Our results do not strongly support an associ­
ation between lead exposure and tremor, and 
suggest no association with cumulative lead 
biomarkers. However, there is some sugges­
tion for an association with blood lead when 
focusing on younger men. Further study in a 
cohort setting with lead biomarker data, but 
using clinical diagnoses of ET, are warranted.
Table 4. Adjusteda difference in total tremor score by lead biomarker quintiles separately by age (years).
Exposure Lead range
Mean difference (95% CI)
< Median age (68.9) ≥ Median age (68.9)
Blood lead (μg/dL)
Quintile 1 0 to 3 Reference Reference
Quintile 2 4 to 4 0.12 (–0.12, 0.36) 0.08 (–0.23, 0.39)
Quintile 3 5 to 5 0.13 (–0.16, 0.42) –0.04 (–0.38, 0.29)
Quintile 4 6 to 7 0.17 (–0.10, 0.44) –0.03 (–0.34, 0.27)
Quintile 5 8 to 28 0.35 (0.03, 0.67) –0.19 (–0.54, 0.15)
p-Trend 0.03 0.20
Patella lead (μg/g)
Quintile 1 –9 to 15 Reference Reference
Quintile 2 16 to 21 –0.15 (–0.42, 0.13) 0.04 (–0.34, 0.42)
Quintile 3 22 to 28 –0.09 (–0.38, 0.20) –0.20 (–0.57, 0.17)
Quintile 4 29 to 39 –0.27 (–0.55, 0.02) –0.17 (–0.56, 0.21)
Quintile 5 40 to 165 0.05 (–0.32, 0.42) 0.02 (–0.35, 0.38)
p-Trend 0.61 0.88
Tibia lead (μg/g)
Quintile 1 –1 to 11 Reference Reference
Quintile 2 12 to 16 0.04 (–0.23, 0.31) –0.06 (–0.47, 0.35)
Quintile 3 17 to 21 0.21 (–0.08, 0.50) –0.23 (–0.61, 0.15)
Quintile 4 22 to 29 0.12 (–0.18, 0.43) –0.02 (–0.39, 0.36)
Quintile 5 30 to 126 0.12 (–0.24, 0.47) –0.24 (–0.61, 0.14)
p-Trend 0.37 0.31
aAdjusted for age, age squared, alcohol intake, cigarette pack-years, and education level.
Table 5. Change in total tremor scores in follow-up assessment where first tremor score is below 4.5, by lead biomarker quintiles.
Linear regression Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 p-Trend
Patella lead      
n 114 86 76 78 73
Range (μg/g) –9 to 15 16 to 21 22 to 28 29 to 39 40 to 165
Crude model (95% CI) 0 (reference) 0.02 (–0.31, 0.36) 0.07 (–0.27, 0.42) 0.06 (–0.28, 0.41) 0.10 (–0.25, 0.45) 0.56
Adjusteda model (95% CI) 0 (reference) 0.06 (–0.28, 0.41) 0.09 (–0.27, 0.45) 0.06 (–0.30, 0.43) 0.12 (–0.28, 0.53) 0.59
Tibia lead   
n 105 86 80 76 80
Range (μg/g) –1 to 11 12 to 16 17 to 21 22 to 29 30 to 126
Crude model (95% CI) 0 (reference) –0.03 (–0.37, 0.31) –0.25 (–0.59, 0.09) –0.18 (–0.54, 0.17) 0.05 (–0.29, 0.40) 0.93
Adjusteda model (95% CI) 0 (reference) –0.02 (–0.36, 0.33) –0.27 (–0.63, 0.09) –0.18 (–0.55, 0.18) 0.06 (–0.33, 0.45) 0.96
aAdjusted for age, age squared, alcohol intake, cigarette pack-years, and education level.
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